These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527 [TBL] [Abstract][Full Text] [Related]
46. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM; Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530 [TBL] [Abstract][Full Text] [Related]
47. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Lieberman A; Ranhosky A; Korts D Neurology; 1997 Jul; 49(1):162-8. PubMed ID: 9222185 [TBL] [Abstract][Full Text] [Related]
48. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up]. Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540 [TBL] [Abstract][Full Text] [Related]
50. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229 [TBL] [Abstract][Full Text] [Related]
51. [Early treatment of Parkinson's disease with levodopa]. Odekerken VJ; Post B; Verschuur CV; de Bie RM Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822 [TBL] [Abstract][Full Text] [Related]
52. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A; Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922 [TBL] [Abstract][Full Text] [Related]
53. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Hauser RA; McDermott MP; Messing S Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616 [TBL] [Abstract][Full Text] [Related]
54. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088 [TBL] [Abstract][Full Text] [Related]
55. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976 [TBL] [Abstract][Full Text] [Related]
56. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306 [TBL] [Abstract][Full Text] [Related]
57. Selegiline slows the progression of the symptoms of Parkinson disease. Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R; Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603 [TBL] [Abstract][Full Text] [Related]
58. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
59. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339 [TBL] [Abstract][Full Text] [Related]
60. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Noyes K; Dick AW; Holloway RG; Value Health; 2006; 9(1):28-38. PubMed ID: 16441522 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]